AZ Tucson의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 17개가 Tucson 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
피험자 모집 중3상
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
피험자 모집 중1상
- Exelixis Clinical Site #1, Tucson
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
피험자 모집 중3상
- The University of Arizona Cancer Center - North Campus, Tucson
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
피험자 모집 중3상
- Research Site, Tucson
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
피험자 모집 중3상
- Southern Arizona VA Health Care System, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
피험자 모집 중1/2상
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- Research Site, Tucson
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
피험자 모집 중2/3상
- Arizona Clinical Research Center, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
피험자 모집 중3상
- The University of Arizona Cancer Center - North Campus, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
피험자 모집 중1/2상
- USOR Arizona Oncology Associates, Tucson
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
피험자 모집 중1/2상
- University of Arizona Cancer Center, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
피험자 모집 중1상
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
피험자 모집 중1상
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
피험자 모집 중건강한 지원자 환영
- University of Arizona Cancer Center, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
피험자 모집 중1/2상
- Research Site 111, Tucson
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
피험자 모집 중1상
- The University of Arizona Cancer Center, Tucson
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Tucson의 다른 연구
- 유방암연구 20개
- 비만연구 18개
- 과체중연구 15개
- 전이성 암연구 14개
- 암 (전체)연구 12개
- 심혈관 질환연구 12개
- 대장직장암연구 11개
- 전립선암연구 11개
- 제2형 당뇨병연구 11개
- 지방간질환연구 10개
- 심부전연구 10개
- 고혈압연구 10개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.